Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 18.83 +0.27 (1.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.56 | 52 Week High | $63.73 | |||
| Open | $18.46 | 52 Week Low | $8.00 | |||
| Day High | $18.89 | P/E | N/A | |||
| Day Low | $18.28 | EPS | $-5.69 | |||
| Volume | 37,283 | |||||
